Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 7, 2023

Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

Business Wire March 9, 2023

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Business Wire March 7, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 3, 2023

Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023

Business Wire February 28, 2023

Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Business Wire February 27, 2023

Seres Therapeutics' Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN

Business Wire February 14, 2023

Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Business Wire February 8, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 3, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 13, 2023

Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

Business Wire January 5, 2023

Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2023

Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

Business Wire November 22, 2022

Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Business Wire November 2, 2022

Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

Business Wire October 27, 2022

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Business Wire October 26, 2022

Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings

Business Wire October 23, 2022

Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

Business Wire October 19, 2022

Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting

Business Wire October 12, 2022

Seres Therapeutics to Present at World Anti-Microbial Resistance Congress

Business Wire September 8, 2022